Epidemiological Services
Solve your European oncology challenges with evidence-based analysis and representative data.
Confident decision-making with data you can trust
Unlock stronger decision-making, targeting, sampling, and understanding of health outcomes with our evidence-based analysis and representative data.
Backed by our strong record of successful HTA submissions, depth of experience, and partnerships with physicians and healthcare providers, you can be confident you’re in good hands.
Rigorous, representative, and regulation-ready
Every TriNetX dataset is representative, regulation-standard, and customizable to your specific study needs, so you can make confident, evidence-based decisions across regions and therapeutic areas.
Global expertise, whenever you need it
From study design to regulatory submission, our team of leading analysts, strategists, and epidemiologists is on hand to provide support and guidance whenever you need them.
With deep oncology and epidemiology experience, we ensure your research is rigorous, your submissions are airtight, and your data is tailored to achieve your specific research goals.
How we support you
Tailored research methodology.
Our research methodologies account for regional service provider distribution, population density, and healthcare infrastructure.
This ensures representative study populations and adaptability across therapeutic areas and geographies, enabling data-driven decisions for resource allocation and treatment pattern analysis across diverse indications.
Mapping key institutions
- We begin with a detailed analysis of the care structure to identify relevant institutions.
- We utilize hospital quality reports, professional directories, and other data sources to map out treatment facilities.
- We define relevant centers through ABC analysis and case-volume assessments to form a robust foundation for further research.
Identification of key treatment centers
- We target both public and private healthcare sectors, including university hospitals, regional clinics, and private practice specialists.
- This comprehensive mapping ensures coverage across the entire care continuum, creating a representative, valid population for further studies.
Targeted data collection
- We collect primary aggregated epidemiological data (e.g. screener surveys) to gather specific patient numbers for targeted conditions.
- We ensure proportional sampling across facility types while mitigating biases (e.g. regional or institutional focus).
- We collect retrospective and real-time data from patient records to support incidence and prevalence extrapolation.
Want to learn more?
Explore our insights
This independently conducted Brief Report, conducted utilizing the TriNetX LIVE™ platform, makes that case in terms that Health Economics and Outcomes Research teams need to confront directly with additional research and contextualization.
This study compares the performance of a classic ML model and a LLM in deriving breast cancer stage from structured EHR data.
Electronic health record RWD sources may be a more viable approach to monitoring
medication use during pregnancy. We estimate exposure to novel therapeutics during pregnancy in a large EHR research network.
Infectious disease research spanning stakeholders and purposes can benefit from the inclusion of real-world data (RWD). The fit for RWD in
studying specific ID research components is not well-established beyond study-specific assessment.
Contact TriNetX
Need to reach out? We’re here to help.
"*" indicates required fields
